DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
FG-3019 is an investigational drug.
There have been 17 clinical trials for FG-3019. The most recent clinical trial was a Phase 1 trial, which was initiated on May 30th 2020.
The most common disease conditions in clinical trials are Fibrosis, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are FibroGen, Jonsson Comprehensive Cancer Center, and [disabled in preview].
There are thirteen US patents protecting this investigational drug and eighty-five international patents.
Recent Clinical Trials for FG-3019
|Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||FibroGen||Phase 3|
|Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease||FibroGen||Phase 2|
|A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)||FibroGen||Phase 3|
Top disease conditions for FG-3019
Top clinical trial sponsors for FG-3019
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|FG-3019||Start Trial||Aerosol pirfenidone and pyridone analog compounds and uses thereof||Avalyn Pharma Inc. (Seattle, WA)||Start Trial|
|FG-3019||Start Trial||Method of treating pancreatic cancer||ChemoCentryx, Inc. (Mountain View, CA)||Start Trial|
|FG-3019||Start Trial||Inhibitors of endoglin activity for the treatment of fibrosis||Tufts Medical Center, Inc. (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|